Rpo LLC Invests $46,000 in Acelyrin, Inc. (NASDAQ:SLRN)

Rpo LLC bought a new stake in Acelyrin, Inc. (NASDAQ:SLRN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 14,693 shares of the company’s stock, valued at approximately $46,000.

Several other hedge funds and other institutional investors have also made changes to their positions in SLRN. Virtu Financial LLC acquired a new stake in Acelyrin in the 3rd quarter valued at $50,000. HighTower Advisors LLC purchased a new stake in shares of Acelyrin in the third quarter worth about $50,000. Intech Investment Management LLC purchased a new stake in shares of Acelyrin in the third quarter worth about $77,000. Virtus Investment Advisers Inc. acquired a new stake in shares of Acelyrin in the third quarter valued at about $176,000. Finally, American Century Companies Inc. raised its holdings in shares of Acelyrin by 146.0% during the 4th quarter. American Century Companies Inc. now owns 78,868 shares of the company’s stock valued at $248,000 after buying an additional 46,802 shares during the period. Institutional investors and hedge funds own 87.31% of the company’s stock.

Acelyrin Stock Up 9.2 %

Shares of SLRN opened at $2.74 on Thursday. The firm has a market cap of $275.95 million, a price-to-earnings ratio of -1.11 and a beta of 1.12. The business’s 50 day moving average is $2.38 and its two-hundred day moving average is $3.69. Acelyrin, Inc. has a 52-week low of $1.85 and a 52-week high of $7.25.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. On average, equities analysts expect that Acelyrin, Inc. will post -2.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on SLRN shares. Citigroup decreased their price target on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Wells Fargo & Company decreased their target price on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, HC Wainwright dropped their price target on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Acelyrin currently has an average rating of “Hold” and an average target price of $9.60.

Insider Transactions at Acelyrin

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now owns 671,753 shares of the company’s stock, valued at $1,840,603.22. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 13.60% of the company’s stock.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.